# Do Teenagers Stay on GLP-1 Drugs? | Buy This GLP

See how prescription gaps, refill patterns and trial completion change estimates of how long adolescents stay on GLP-1 drugs.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/do-teens-stay-on-glp1-drugs
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Do Teenagers Stay on GLP-1 Drugs?

U.S. claims, Danish prescription records and the STEP TEENS trial each measured continued treatment differently.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Two measures of continued GLP-1 treatment · U.S. pediatric patients · 20.3% · Persistent refill pattern among 1,139 patients · Danish adolescents ages 12–17 · 54% · Estimated prescription coverage at one year · The studies used different definitions.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   About one in five pediatric patients in one U.S. claims study fell into the persistent-refill group over 12 months.
-   In Denmark, 54% of 12-to-17-year-olds had estimated prescription coverage at one year. That measure allows for earlier gaps.
-   Clinical trial completion and prescription coverage answer different questions.

Studies of [how long people stay on GLP-1 treatment](https://buythisglp.com/research/how-long-do-people-stay-on-a-glp1) can count uninterrupted refills, a prescription covering a particular date or completion of a trial. Those definitions help explain why the reported numbers for adolescents differ.

## What the U.S. claims study measured

Researchers followed a cohort of 1,139 pediatric patients and 201,229 adults with obesity and no diabetes using U.S. commercial insurance claims from 2021 to 2023. They grouped people by monthly prescription coverage over the year after starting treatment. Among pediatric patients, 20.3% fell into the persistent-user group, compared with 30.7% of adults [\[1\]](https://buythisglp.com/research/do-teens-stay-on-glp1-drugs#ref-1). Others had different refill patterns, including intermittent coverage. The study could not determine which doses people took or why they had gaps.

## What the Danish prescription registry found

At one year, 54% of the adolescents ages 12 to 17 and 37% of the young adults ages 18 to 24 had estimated prescription coverage. That allowed for a gap followed by a restart. Across both age groups, 38% had estimated coverage and 22% had stayed on treatment without a gap under the study definition [\[2\]](https://buythisglp.com/research/do-teens-stay-on-glp1-drugs#ref-2). The Danish study included multiple drugs and some patients with diabetes, so its rates cannot be directly compared with the U.S. data.

## What happened in STEP TEENS?

The [review of lifestyle treatment and obesity medicines in teens](https://buythisglp.com/research/the-drug-alone-was-never-the-winner) compares weight outcomes across several treatment approaches. The claims studies above measured how long people kept filling prescriptions.

In STEP TEENS, 180 of 201 randomized participants completed 68 weeks of assigned treatment, about 90% in both the semaglutide and placebo groups [\[3\]](https://buythisglp.com/research/do-teens-stay-on-glp1-drugs#ref-3). Both groups received lifestyle support and followed the study schedule. Completion in this setting does not establish how many adolescents would keep filling prescriptions in routine care.

If prescription access, side effects or treatment goals change, families can discuss next steps with the clinician managing the adolescent’s care.

## Frequently asked

How many teens are still taking a GLP-1 after one year?

In Denmark, 54% of ages 12 to 17 had estimated prescription coverage at one year, even if they had interrupted treatment earlier. A U.S. study put 20.3% of pediatric patients into a persistent-refill group over 12 months. The two studies used different measures.

Do prescription claims show whether someone took every dose?

Claims show prescription fills. Researchers use them to estimate treatment coverage, but the records do not verify individual doses.

## Sources

1.  \[1\] Huang W, et al. (2026). Real-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity Diabetes, Obesity & Metabolism. [PMID 42755139](https://pubmed.ncbi.nlm.nih.gov/42755139/)
2.  \[2\] Kildegaard H, et al. (2026). Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025 Obesity. [PMID 42252120](https://onlinelibrary.wiley.com/doi/10.1002/oby.70234)
3.  \[3\] Weghuber D, et al. (2022). Once-Weekly Semaglutide in Adolescents with Obesity New England Journal of Medicine. [PMID 36322838](https://www.nejm.org/doi/full/10.1056/NEJMoa2208601)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
